Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andrew Scharenberg describes the technical innovations they have come up with to help make it succeed

He describes Umoja's numerous platforms that are aimed at maximizing in vivo success, including the company's proprietary lentiviral vector, a rapamycin based architecture to help the CAR-T cells expand and survive, and a tumor tagging technology that may help in tricky solid tumor settings. Umoja is the first company to have an IND cleared for an in vivo program in the United States.